Brussels, 17 July 2012: The EU Commission has published today the draft legal proposal on the revision of the regulatory framework for clinical trials in Europe.

EBE Executive Director (acting) Mrs Titta Rosvall-Puplett comments on the EU Commission proposed new regulation:

Brussels, 26 June 2012 - At the occasion of its General Assembly held on 26 June, as part of the EFPIA Annual Meeting, Mr. Roberto Gradnik, MD has been appointed as President of EBE (European Biopharmaceutical Enterprises).

Strasbourg, 16 November 2011: EBE and EDMA organised a lunch-debate at the European parliament in Strasbourg

Personalised Medicine and Companion Diagnostics: Innovative Patient Solutions for Future Healthcare. For those who were interested in discussing Companion Diagnostics and Personalised Medicine, EBE and EDMA decisively contributed to fulfil this demand by organising a lively event at the European Parliament during its November plenary session.

Brussels, 21 June 2011: EBE held its General Assembly on 14 June, as part of the EFPIA Annual Meetings held in Brussels on 14-15 June.

The European Biopharmaceutical Enterprises (EBE) is pleased to announce the appointment of Alexandre Delacoux as new EBE Executive Director.

Brussels, 12 January 2011 – The EBE Board of Directors confirmed the appointment of Alexandre Delacoux to become the new EBE Executive Director, following the departure of Emmanuel Chantelot who has been instrumental during the past five years in the continuous development of EBE and whose achievements he will build upon.

Brussels, 29 November 2010: Today EBE and EuropaBio’s Joint Rare Diseases and Orphan Medicinal Products Task Force released an assessment* of the EU’s Orphan Medicinal Products (OMP) Regulation evaluating the extent to which this legislation has impacted research into rare diseases and the availability of new medicines to treat rare diseases over the last ten years.

European Biopharmaceutical Enterprises Elects Marc de Garidel as New EBE President and Appoints New Directors on the EBE Board

Brussels, 9 July 2010 – At its annual General Assembly held in London, the members of European Biopharmaceutical Enterprises (EBE) unanimously elected Marc de Garidel (Amgen) as the new EBE President for a 2-year term. Mr. de Garidel is Vice-President South Region of Amgen International, based in Zug, Switzerland. He had already been an active member of the EBE Board as EBE Vice-President & Treasurer since April 2006. Marc de Garidel takes over the EBE presidency from Dr. Carlo Incerti, Senior Vice President Global Market Access at Genzyme, who will continue to sit on the EBE Board as Vice-President.

Together for Rare Diseases – All Stakeholders Celebrate 10 Years of Success of the EU Regulation on Orphan Medicines at the European Parliament

Brussels, 2 June 2010: The joint EBE-EuropaBio Task Force on Rare Diseases and Orphan Medicines organised a special reception yesterday at the European Parliament, hosted by Madame Françoise Grossetête, MEP, to celebrate 10 years of success of the EU Regulation on Orphan Medicinal Products adopted in December 1999.

Brussels, December 1st, 2009: EBE, the European Biopharmaceutical Enterprises and the European Commission’s Enterprise and Industry Directorate General today jointly presented a workshop on access to finance for small and medium-sized biopharmaceutical companies in Europe. The workshop is a major step forward in finding new solutions to support and underpin at-risk European biopharmaceutical SMEs, which have been hit hard by the economic challenges of the global financial crisis. The workshop marked the release of a Commission-funded study on the financing of biopharmaceutical product development in Europe. The study highlights the decreasing levels of venture capital available for biopharmaceutical SMEs, as well as the impact of the global economic crisis on access to liquidities and credit.

Bad Hofgastein, 1 October 2009: The European Biopharmaceutical Enterprises (EBE) hosted a lunch workshop co-sponsored by EBE, Novartis and Roche during the European Health Forum Gastein on “Biopharmaceuticals: Balancing Benefits and Risks - Sharing Responsibility”. The event highlighted the need to share responsibility amongst key stakeholders during the development process of a medicinal product, from its research and conception until its release on the market. Sharing responsibility would help ensure a balanced approach that reflects the interests of all parties concerned.

“Europe and its rare disease patients will benefit,” say stakeholders
Brussels, 11 June 2009

On June 9, Health Ministers from the 27 EU Member States unanimously signed up to a series of political commitments on behalf of Europe’s rare disease patients, by adopting a Council Recommendation on a European Action in the Field of Rare Diseases1. This means that Member States have committed to creating a rare disease action plan at national level and to cooperating at a European level on this important and unmet public health priority.

One in five of Europe's small biopharmaceutical companies facing financial difficulty

Brussels, 16th March 2009 – One of Europe’s most innovative sectors is facing potential catastrophe in the current financial crisis, as many small European biopharmaceutical companies face increasing difficulties to access the funding they need to keep afloat. A new study by French research group Alcimed, on behalf of the European Biopharmaceutical Enterprises, paints a grim picture of the impact of the crisis on the sector.

EuropaBio and EBE congratulate EU leaders on the Commission Communication on Rare Diseases and calls for European action to turn principles and proposals into reality

Industry welcomes the special conference on Rare Diseases Research: Building on Success, organised by DG Research to foster increased research, renewed Community funding and new partnerships to combat rare diseases.   

Brussels, 31 May 2007 – Today, the Council of the European Union adopted in first reading the Advanced Therapy Medicinal Products Regulation (COD/2005/0227), which follows the adoption of a compromise package by the European Parliament on 25 April.

Companies researching and developing treatments for rare diseases welcome draft Commission guideline providing legal certainty on market exclusivity for Orphan Medicines

Exclusive Berlin Conference Catalysed
New Partnerships Between Pharma & Biotech Companies

Berlin 13-14 December: European Small & Medium-sized biopharmaceutical companies had the opportunity to network with counterparts from the larger pharmaceutical companies at a private Business Development Event, organised by the industry associations European Biopharmaceutical Enterprises (EBE) and BIO Deutschland.

But better patient access to approved orphan medicines and additional economic incentives in most Member States needed. 

Industry Congratulates EMEA for Open Discussions of Biosimilar Guidelines;
Urges that Patient Safety Not Be Compromised

EBE and EFPIA Welcome European Commission's Initiative on Advanced Therapies.

EFPIA AND EBE WELCOME EUROPEAN COMMISSION’S INITIATIVE
ON ADVANCED THERAPIES

Brussels, 16 November 2005 - The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Emerging Biopharmaceutical Enterprises (EBE) broadly welcome the European Commission’s proposal for a new integrated EU legal framework in support of gene, cell and tissue-based therapies  as an important step for patients in the key area of biotechnology.

EBE Press Release on EMEA-DIA Workshop on the Guidelines for Development and Approval of Similar Biological Medicinal Products.